Holland Capital: Investment Strategy, Funds, Portfolio Companies, and Firm Profile
1. What Is Holland Capital?
Holland Capital is a Dutch private capital firm investing through venture, growth, and buyout strategies. Rolf Deves founded the business in Amsterdam in 1981 under the Holland Venture name. The firm adopted its current name on January 1, 2019, reflecting activities extending beyond venture investing. It operates from Amsterdam and Düsseldorf and identifies the Benelux and Germany as its investment markets.
Healthcare and technology remain its central sector labels, with agrifood technology also appearing in its investment mandate. Its activities include financing expansion, acquiring existing shares, and supporting acquisition-led development. Both majority and minority investments are possible.
For this directory, the supplied classification of Direct private equity / buyouts is relevant but incomplete. Holland Capital is better understood as a European sector-focused investor combining lower-middle-market private equity with venture and growth capital. These are editorial classifications of its investment model, not assessments of investment performance.
2. Holland Capital at a Glance
- Firm name
- Holland Capital
- Firm type
- Independent private capital firm with venture, growth, and buyout activities.
- Founded
- 1981, initially as Holland Venture.
- Founder
- Rolf Deves.
- Headquarters
- Amsterdam, the Netherlands; an additional office is in Düsseldorf, Germany.
- Parent organization
- Described as independent. A larger parent investment group was not verified.
- Main investment markets
- Benelux and Germany; individual funds can have more specific mandates.
- Geography group
- Europe.
- Directory segments
- Direct private equity / buyouts; sector-specialist private equity; lower-middle-market investors; growth equity and venture crossover.
- Principal strategies
- Venture & Growth and Growth & Buy-Out. The team directory also identifies Small Cap Buy-Out roles.
- Ownership preference
- Flexible: majority and minority stakes are possible.
- Typical company profile
- Growth-oriented SMEs, with maturity and financial characteristics varying by strategy.
- Sector focus
- Healthcare, technology, and agrifood technology.
- Important publicly identifiable vehicles
- Growth and Buy-Out Fund V; Growth and Buy-Out Fund IV; Venture & Growth Fund IV; and Holland Capital Fund VI. Identification of a vehicle does not establish its fundraising or deployment status.
- Current leadership
- Ewout Prins and Hubert Verbeek, Managing Partners; Margot Engels, Operational Partner & CEO.
- Current status
- Operating investment firm at the October 13, 2026 review cutoff.
- Official website
- Holland Capital Official Website
The organizational and strategy fields distinguish the investment firm from its management company and individual funds. The leadership titles above reflect the firm’s team directory; fund identification reflects its announcements and product disclosures.
3. Who Founded Holland Capital, and How Is the Firm Organized?
Rolf Deves established Holland Venture in 1981. The firm’s historical account describes its initial Amsterdam office on the Rokin and support from Amro Bank and Pierson, Heldring & Pierson. Those banks were founding institutional supporters, not substitutes for the named operating founder.
Hubert Verbeek and Ewout Prins joined the business in 2000 and took over its leadership in 2009. They remain listed as Managing Partners. Margot Engels is listed as Operational Partner & CEO, combining an executive role with healthcare operating responsibilities. Their later leadership should not be confused with the firm’s original founding.
The organization has professionals assigned to Venture & Growth and Growth & Buy-Out, with healthcare and technology responsibilities differentiated within those activities. Its team directory also contains Small Cap Buy-Out positions, operating roles, finance, legal, investor-relations, and ESG functions. This supports an organizational description broader than a single buyout team, without establishing a separately capitalized fund for every team label.
Holland Capital Management B.V. is identified as the manager in fund disclosures. The investment manager, its funds, and the businesses those funds own are distinct entities. Detailed ownership of the management company was not verified, so fund investors should not automatically be characterized as shareholders of the manager.
4. What Is the History of Holland Capital?
Holland Capital’s development is a progression from an early Dutch venture-capital business into a sector-focused organization offering several forms of company equity financing. The following milestones help explain that progression.
- 1981: establishment in Amsterdam. Rolf Deves founded Holland Venture. Its original business developed at a time when institutional participation in smaller Dutch companies was still relatively new.
- 2000 to 2009: leadership transition. Hubert Verbeek and Ewout Prins joined in 2000 and succeeded Deves in leadership in 2009. This was a transition within an existing firm, not the creation of a new investment business.
- 2019: adoption of the Holland Capital name. The change became effective on January 1, 2019. The firm connected the rebranding to a wider remit encompassing mature companies, international ambitions, and buy-and-build strategies.
- 2020: Growth and Buy-Out Fund IV. On February 11, 2020, Holland Capital announced a new €120 million fund for growth and buyout investments. Its stated approach included management buyouts and growth financing in healthcare and technology.
- 2021: venture-and-growth development and German expansion plans. Its anniversary materials identified Venture & Growth Fund IV and discussed plans for a German office. Subsequent announcements identify an operating Düsseldorf office. The announcement of expansion and evidence of an established office are separate milestones.
- 2024 onward: a larger buyout vehicle and another disclosed fund. Growth and Buy-Out Fund V reached a first-and-final closing of €225 million, announced March 5, 2024. At the 2026 review cutoff, the firm’s product disclosures also identify Holland Capital Fund VI, whose documented strategy concerns scaling healthcare and technology businesses.
These milestones establish continuity across the Holland Venture and Holland Capital names. They do not, by themselves, establish superior returns, a complete historical fund count, or the current ownership of every predecessor investment.
5. What Investment Strategies Does Holland Capital Pursue?
Holland Capital’s central distinction is between Venture & Growth and Growth & Buy-Out. Its overall strategy emphasizes businesses with growth opportunities, differentiated products or services, and management teams capable of developing the company. Capital is accompanied by involvement in strategy and operational development.
Growth and buyout investing
The established-company strategy can provide new growth capital, purchase existing shares, or combine the two. Holland Capital expressly allows both majority and minority positions. It should therefore not be presented as an exclusively control-oriented investor. Management buyouts and acquisition-led expansion are documented elements of its approach.
Fund V’s product disclosure describes a lower-middle-market focus and international growth potential. The stated objective is to help businesses grow, professionalize, and strengthen their strategic position. That is a description of the manager’s investment proposition, not independent proof that each company achieves a particular scale or valuation.
Venture and growth investing
The newer Fund VI disclosure targets companies beyond the early-stage phase, with validated product-market fit, sustainable recurring revenue, and growth potential. This vehicle-specific mandate is more precise than treating all venture activity as startup financing.
Analytically, Holland Capital is best understood as combining company-building and ownership-transition investing. The balance between growth capital, shareholder liquidity, governance rights, and operating involvement must be established for the particular transaction rather than inferred from the firm’s name.
6. What Funds Does Holland Capital Manage?
Holland Capital invests through identifiable fund vehicles rather than a single undifferentiated pool of corporate capital. Publicly documented vehicles include growth-and-buyout funds, venture-and-growth funds, and earlier sector-oriented funds. Their names and numbering should not be treated as interchangeable strategies.
- Holland Capital Growth and Buy-Out Fund V
- Holland Capital announced a first-and-final closing at the €225 million hard cap on March 5, 2024. The announced mandate covers medium-sized Dutch and German companies in healthcare, technology, and agrifood technology. Its stated plan for 15 to 20 platform investments was an investment objective, not a count of completed acquisitions.
- Holland Capital Growth and Buy-Out Fund IV
- The February 11, 2020 launch announcement reported €120 million raised and described management-buyout and growth-capital financing. The announcement is evidence of that fundraising amount; it is not presented here as a separately verified first-and-final closing.
- Holland Capital Venture & Growth Fund IV
- The firm’s historical fund timeline identifies this vehicle in 2021. Its existence is documented, but a fund size and current deployment status were not verified for this profile.
- Holland Capital Fund VI Coöperatief U.A.
- A published product disclosure identifies this vehicle, Holland Capital Management B.V. as manager, and a healthcare-and-technology scaling strategy. A final-close amount was not verified. The numeral VI should not be assumed to mean that this is simply the successor to Growth and Buy-Out Fund V.
In its July 17, 2025 update, the firm reported €500 million in managed capital. That is a firm-level reported figure, not the size of one strategy, an equity investment ticket, or a newly measured October 2026 amount. The individual fund figures should not be added to it.
7. What Types of Companies Does Holland Capital Invest In?
Holland Capital’s company profile depends on the strategy and vehicle. Its stated focus on SMEs does not imply that every investment has the same revenue, profitability, ownership structure, or capital requirement.
In its December 30, 2024 strategy update, the firm described Growth & Buy-Out candidates with EBITDA of €1 million to €10 million. Smaller businesses could be considered as portfolio-company add-ons, while larger businesses could be considered with a co-investor. The same update described Venture & Growth candidates with revenue of €0 million to €5 million and EBITDA below €1 million, including cash-flow-negative accelerated-growth situations. These are dated company-profile guidelines, not enterprise-value or equity-ticket ranges.
Fund VI’s published mandate adds a different, vehicle-specific emphasis on companies that have already demonstrated product-market fit and recurring revenue. Accordingly, an early-stage business and a more developed growth company should not assume that they fit the same fund merely because both operate in technology.
Management buyouts are explicitly documented. Platform development and add-on acquisitions are also visible in the firm’s investment approach and portfolio activity. Founder liquidity, expansion financing, and consolidation situations may therefore be consistent with its model, but that interpretation is not a universal eligibility rule. A single firm-wide equity-check range, mandatory ownership percentage, and standard leverage requirement were not verified.
8. Which Industries Does Holland Capital Focus On?
Holland Capital organizes its investment proposition around healthcare and technology, with agrifood technology also documented. These are broad sector groupings rather than one narrowly defined industry. Its technology remit includes software, IT services, specialist consultancies, advanced equipment, and technologies associated with the energy transition. Healthcare exposure includes services, medical devices, diagnostics, and digital health.
Software and technology-enabled services
Enterprise software and SaaS are substantively relevant to the firm’s exposure. For example, Sibi develops software supporting healthcare employees’ engagement and employability. This illustrates the overlap between technology and healthcare rather than a separation into unrelated investment markets.
Healthcare equipment and supporting infrastructure
Medical devices and diagnostics are another relevant industry category. Lopital develops and supplies hygiene, transfer, and mobility equipment. The Medexs/Van Vliet Healthcare Group combines medical-facility expertise with equipment, consumables, and servicing. These are different business models within healthcare exposure.
Agrifood technology
AgTech and FoodTech reflect a documented investment area. Gullimex provides measurement, data-recording, and quality-control solutions serving food and medical customers. Analytically, this is an example of technology supplying regulated customer workflows, not evidence that Holland Capital invests indiscriminately across food production.
9. Where Does Holland Capital Invest?
Holland Capital’s headquarters and principal Dutch office are in Amsterdam, in the Netherlands. Its additional office is in Düsseldorf. The firm’s stated investment market is the Benelux and Germany, which supports the directory’s Europe geography group.
The firm-level geographic description is not identical to every fund’s mandate. Growth and Buy-Out Fund V’s fundraising announcement specifically identifies Dutch and German companies. Fund VI’s product disclosure identifies the Benelux and Germany. Readers should therefore check the relevant vehicle rather than assume that a general regional description establishes eligibility for all funds.
Cross-border development is also visible at the portfolio-company level. Lopital operates internationally, while Medexs and Van Vliet Healthcare described ambitions to expand beyond the Netherlands. Such exposure can arise through a company’s customers, operations, distribution, or acquisitions; it does not establish that the manager has an unrestricted global investment mandate.
Analytically, the geographic proposition combines proximity to Dutch and German businesses with support for their international development. Headquarters location, investment mandate, and portfolio-company sales geography should remain separate concepts.
10. How Does Holland Capital Seek to Create Value?
Holland Capital describes value creation as a collaboration with management on strategic development and operational improvement. Its investment proposition combines capital, sector knowledge, an entrepreneur network, and active shareholder involvement. These are firm-described capabilities, not independently established results at every portfolio company.
Internal operating resources
The team directory identifies operational partners, an operational investment role, and a Value Engineer, alongside investment professionals and central support functions. The firm also states that its operational team can contribute to specific company projects when needed. This supports the existence of internal operating resources, but not an assumption that identical resources are deployed across all investments.
Growth and organizational development
Fund VI describes four scaling priorities: go-to-market acceleration, organizational design, data-driven decision-making, and internationalization. The framework is vehicle-specific evidence of an operating approach; it is not proof of completed improvements or quantified benefits.
Acquisition-led development
Kids Lodge’s acquisition of Donkey and Lopital’s acquisition of Culsana illustrate portfolio-company buy-and-build activity. In Lopital’s case, the stated rationale concerned complementary products and customers. These transactions demonstrate acquisition activity, not independently measured integration synergies.
Governance and sustainability
Fund V’s disclosures address management structures, employee relations, remuneration, tax compliance, and environmental and social characteristics. Its Article 8 classification should not be equated with a sustainable-investment objective or verified impact performance. No portfolio-wide AI deployment, procurement savings, or standardized pricing program was verified for this profile.
11. What Types of Business Situations May Fit Holland Capital?
The following situations are analytical interpretations of Holland Capital’s documented strategies, not investment advice or confirmation of current appetite.
- An established SME seeking expansion capital. The firm’s growth financing and lower-middle-market mandate are consistent with businesses that need capital and organizational development to pursue further growth.
- A management-led ownership transition. Management buyouts are explicitly identified in the Growth and Buy-Out approach. This does not establish that every succession or shareholder-liquidity situation meets the firm’s requirements.
- A platform with credible acquisition opportunities. The documented portfolio activity is consistent with consolidation situations where acquisitions can extend services, product ranges, or geographic coverage. The commercial case and integration capacity would remain company-specific questions.
- A healthcare or technology company preparing to scale. Fund VI’s criteria are consistent with companies that have moved beyond initial product validation and need support building a larger commercial and organizational footprint.
The firm’s willingness to consider majority and minority structures means that ownership can be negotiated around the transaction. It should not be interpreted as unlimited flexibility on valuation, governance, capital requirements, or company maturity.
12. What Distinguishes Holland Capital?
Several documented characteristics help distinguish Holland Capital’s investment proposition. They describe its model rather than establish superiority over another investor.
- A combination of investment stages. Venture, growth, and buyout activities coexist within the organization. The relevant investment team and vehicle therefore matter as much as the overall firm name.
- Concentrated sector coverage. Healthcare and technology provide the core investment orientation, with agrifood technology extending the documented remit. This is sector concentration, not evidence of expertise in every subindustry within those broad categories.
- Internal operating involvement. Operational roles and project support sit alongside the investment organization. Their existence differentiates the proposition from capital-only financing, although availability does not establish deployment or effectiveness in every company.
- A regional base with international company-development ambitions. The documented mandates focus on nearby European markets while seeking companies with potential to expand internationally. This combines regional investment focus with cross-border portfolio development.
Analytically, these characteristics make Holland Capital a sector-focused company-development investor with multiple equity approaches. A conventional “buyout firm” label captures an important business line but leaves out its growth and venture activities. Its fundraising amounts and long operating history do not establish investment quality or future returns.
13. How Should Holland Capital Be Understood Today?
At the October 13, 2026 review cutoff, Holland Capital is best understood as an operating European private capital firm with distinct venture-and-growth and growth-and-buyout capabilities. Its team continues to identify Ewout Prins and Hubert Verbeek as Managing Partners and Margot Engels as Operational Partner & CEO.
The central proposition remains sector-focused investment combined with support for company development. Recent affirmative ownership evidence includes the firm’s 2026 descriptions of continuing shareholding in Kids Lodge and Lopital. These examples establish specific relationships at their disclosed dates, not a same-day measurement of the complete portfolio.
The fund picture is broader than the €225 million Growth and Buy-Out Fund V announced in 2024. Published Fund VI materials identify another vehicle with a scaling-oriented mandate, but its final-close amount was not verified. The €500 million managed-capital figure reported in July 2025 should likewise retain that reporting date rather than be treated as a newly measured 2026 total.
Its inclusion in Umbrex’s Top 1000 Global Private Equity Firms collection is a research classification. “Top 1000” is not a verified ranking of size, returns, prestige, investment quality, or suitability for a particular company. The portfolio table is selective, and unverified fund assignments remain expressly qualified.
14. Frequently Asked Questions
Who founded Holland Capital?
Rolf Deves founded the business in Amsterdam in 1981 under the Holland Venture name. Amro Bank and Pierson, Heldring & Pierson were institutional supporters of its establishment, distinct from the named founder.
Is Holland Capital the same firm as Holland Venture?
Yes, in the scope of this profile. The continuing investment business adopted the Holland Capital name on January 1, 2019. The change reflected activities extending beyond venture capital into mature-company growth and buyout investing.
Does Holland Capital invest only through control buyouts?
No. Its documented approach allows majority and minority investments, new growth capital, and purchases of existing shares. The ownership structure and applicable strategy must be established for the particular investment rather than assumed.
Which markets does Holland Capital target?
The firm identifies the Benelux and Germany as its investment markets. Individual vehicles can be more specific: Growth and Buy-Out Fund V’s announcement identifies Dutch and German companies. Office location is not a substitute for a fund’s mandate.
Which industries are central to its strategy?
Healthcare and technology are central, with agrifood technology also documented. Relevant business models include healthcare services, medical equipment, diagnostics, digital health, software, IT services, and technology serving food-industry workflows. Sector exposure does not establish coverage of every adjacent industry.
How large was Growth and Buy-Out Fund V?
Holland Capital announced a first-and-final closing at €225 million on March 5, 2024. That is the fund’s disclosed fundraising amount, not the firm’s total managed capital, a company valuation, or an investment-ticket size.